Enzo Biochem (ENZ) 10-Q 13 Mar 17 2017 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jan. 31, 2017	Mar. 01, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	ENZO BIOCHEM INC
Document Type	10-Q
Current Fiscal Year End Date	--07-31
Entity Common Stock, Shares Outstanding		46,292,216
Amendment Flag	false
Entity Central Index Key	316,253
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jan. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jan. 31, 2017	Jul. 31, 2016
Current assets:
Cash and cash equivalents	$ 62,427	$ 67,777
Accounts receivable, net of allowances	15,355	14,592
Inventories	7,115	6,971
Prepaid expenses and other	1,982	2,057
Total current assets	86,879	91,397
Property, plant and equipment, net	8,168	8,214
Goodwill	7,452	7,452
Intangible assets, net	3,560	4,422
Other assets	332	336
Total assets	106,391	111,821
Current liabilities:
Accounts payable – trade	10,285	9,857
Accrued liabilities	6,421	8,211
Loan payable		1,557
Other current liabilities	859	943
Total current liabilities	17,565	20,568
Other liabilities	1,098	1,699
Total liabilities	18,663	22,267
Commitments and contingencies
Stockholders’ equity:
Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 46,292,216 at January 31, 2017 and 46,267,619 at July 31, 2016	463	463
Additional paid-in capital	326,751	326,288
Accumulated deficit	(241,923)	(239,396)
Accumulated other comprehensive income	2,437	2,199
Total stockholders’ equity	87,728	89,554
Total liabilities and stockholders’ equity	$ 106,391	$ 111,821

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares	Jan. 31, 2017	Jul. 31, 2016
Preferred Stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred Stock, shares authorized	25,000,000	25,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common Stock, shares authorized	75,000,000	75,000,000
Common Stock, shares issued	46,292,216	46,267,619
Common Stock, shares outstanding	46,292,216	46,267,619

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2017	Jan. 31, 2016	Jan. 31, 2017	Jan. 31, 2016
Revenues:
Clinical laboratory services	$ 18,837	$ 17,523	$ 37,395	$ 34,613
Product revenues	6,983	6,578	14,409	14,265
Royalty and license fee income	440	459	740	859
Total revenues	26,260	24,560	52,544	49,737
Operating costs, expenses and legal settlements, net:
Cost of clinical laboratory services	11,052	10,535	21,948	20,867
Cost of product revenues	3,520	3,206	6,829	6,817
Research and development	483	861	1,305	1,728
Selling, general and administrative	11,165	11,280	22,639	21,505
Provision for uncollectible accounts receivable	679	459	1,348	1,163
Legal fee expense	370	2,411	742	4,012
Legal settlements, net		(11,650)		(18,450)
Total operating costs, expenses and legal settlements, net	27,269	17,102	54,811	37,642
Operating income (loss)	(1,009)	7,458	(2,267)	12,095
Other income (expense):
Interest	79	(42)	125	(82)
Other	24	11	143	65
Foreign exchange loss	(94)	(388)	(455)	(518)
Income (loss) before income taxes	(1,000)	7,039	(2,454)	11,560
Provision for income taxes	(53)	(207)	(73)	(294)
Net income (loss)	$ (1,053)	$ 6,832	$ (2,527)	$ 11,266
Net income (loss) per common share:
Basic (in Dollars per share)	$ (0.02)	$ 0.15	$ (0.05)	$ 0.24
Diluted (in Dollars per share)	$ (0.02)	$ 0.15	$ (0.05)	$ 0.24
Weighted average common shares outstanding:
Basic (in Shares)	46,292	46,077	46,282	46,070
Diluted (in Shares)	46,292	46,518	46,282	46,353

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2017	Jan. 31, 2016	Jan. 31, 2017	Jan. 31, 2016
Net income (loss)	$ (1,053)	$ 6,832	$ (2,527)	$ 11,266
Other comprehensive income (loss):
Foreign currency translation adjustments	(16)	226	238	288
Comprehensive income (loss)	$ (1,069)	$ 7,058	$ (2,289)	$ 11,554

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 6 months ended Jan. 31, 2017 - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Jul. 31, 2016	$ 463	$ 326,288	$ (239,396)	$ 2,199	$ 89,554
Balance (in Shares) at Jul. 31, 2016	46,267,619
Net loss for the period ended January 31, 2017			(2,527)		(2,527)
Vesting of restricted stock (in Shares)	1,501
Exercise of stock options		71			$ 71
Exercise of stock options (in Shares)	23,096				23,096
Share-based compensation charges		392			$ 392
Foreign currency translation adjustments				238	238
Balance at Jan. 31, 2017	$ 463	$ 326,751	$ (241,923)	$ 2,437	$ 87,728
Balance (in Shares) at Jan. 31, 2017	46,292,216

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jan. 31, 2017	Jan. 31, 2016
Cash flows from operating activities:
Net income (loss)	$ (2,527)	$ 11,266
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization of property, plant and equipment	1,023	1,059
Amortization of intangible assets	819	843
Provision for uncollectible accounts receivable	1,348	1,163
Deferred income tax benefit		(5)
Share-based compensation charges	392	221
Accrual for share-based 401(k) employer match expense	354	439
Foreign exchange loss	420	333
Changes in operating assets and liabilities:
Accounts receivable	(2,170)	(1,952)
Other receivables		6,650
Inventories	(238)	(20)
Prepaid expenses and other	67	350
Accounts payable – trade	238	693
Accrued liabilities, other current liabilities and other liabilities	(2,558)	(983)
Total adjustments	(305)	8,798
Net cash provided by (used in) operating activities	(2,832)	20,064
Cash flows from investing activities:
Capital expenditures	(689)	(943)
Security deposits and other	2	2
Net cash used in investing activities	(687)	(941)
Cash flows from financing activities:
Proceeds from borrowings under Credit Agreement	40,694	44,378
Repayments under Credit Agreement	(42,251)	(44,378)
Installment loan and capital lease obligation payments	(323)	(258)
Proceeds from the exercise of stock options	71	66
Net cash used in financing activities	(1,809)	(192)
Effect of exchange rate changes on cash and cash equivalents	(22)	(24)
Increase (decrease) in cash and cash equivalents	(5,350)	18,907
Cash and cash equivalents - beginning of period	67,777	18,109
Cash and cash equivalents - end of period	$ 62,427	$ 37,016

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jan. 31, 2017
Disclosure Text Block [Abstract]
Basis of Accounting [Text Block]	Note 1 – Basis of Presentation The accompanying consolidated financial statements include the accounts of Enzo Biochem, Inc. and its wholly-owned subsidiaries, Enzo Life Sciences, Enzo Clinical Labs, Enzo Therapeutics and Enzo Realty LLC, collectively or with one or more of its subsidiaries referred to as the “Company” or “Companies”. The consolidated balance sheet as of January 31, 2017, the consolidated statements of operations and comprehensive income (loss) for the three and six months ended January 31, 2017 and 2016, and the consolidated statements of stockholders’ equity and cash flows for the six months ended January 31, 2017 and 2016 are unaudited. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position and operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed or omitted. The consolidated interim financial statements should be read in conjunction with the consolidated financial statements for the year ended July 31, 2016 and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission. The consolidated balance sheet at July 31, 2016 has been derived from the audited financial statements at that date. The results of operations for the three and six months ended January 31, 2017 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2017. Effect of New Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers: Topic 606 In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02 – Leases (Topic 842) In March 2016, the FASB issued ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting,” In April 2015, the FASB issued ASU No. 2015-03 Interest – Imputation of Interest. In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory (Topic 330). In January 2017, the FASB issued ASU 2017-04 Intangibles – Goodwill and Other – Simplifying the Test for Goodwill Impairment. The ASU eliminates step two in the current two-step process so that any goodwill impairment is measured as the amount by which the reporting unit’s carrying amount exceeds its fair value. The ASU is effective for the Company in the first quarter of 2020 with early adoption permitted. The Company does not expect the adoption of this ASU to have a material impact on our consolidated financial statements. We reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations.

Net income (loss) per share

Net income (loss) per share	6 Months Ended
	Jan. 31, 2017
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 2 – Net income (loss) per share Basic net income (loss) per share represents net income (loss) divided by the weighted average number of common shares outstanding during the period. As a result of the net loss for the three and six months ended January 31, 2017 diluted weighted average shares outstanding are the same as basic weighted average shares outstanding, and do not include the potential common shares from stock options and unvested restricted stock because to do so would be antidilutive. For the three and six months ended January 31, 2017, the number of potential common shares (“in the money options”) and unvested restricted stock excluded from the calculation of diluted earnings per share was 888,000 and 804,000, respectively. For the three and six months ended January 31, 2016, approximately 440,000 and 281,000 weighted average stock options were included in the calculation of diluted weighted average shares outstanding. For the three and six months ended January 31, 2017, the effect of approximately 494,000 and 247,000 of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income per share because their effect would be anti-dilutive. For the three and six months ended January 31, 2016, the effect of approximately 235,000 and 305,000 of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income per share because their effect would be anti-dilutive.

Supplemental disclosure for sta

Supplemental disclosure for statement of cash flows	6 Months Ended
	Jan. 31, 2017
Supplemental Cash Flow Elements [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	Note 3 - Supplemental disclosure for statement of cash flows For the six months ended January 31, 2017 and 2016, income taxes paid by the Company were $996 and $53, respectively . For the six months ended January 31, 2017 and 2016, interest paid by the Company was $77. For the six months ended January 31, 2017 and 2016, the Company financed $69 and $76 respectively, in machinery and transportation equipment under installment loans. During the six months ended January 31, 2017, the Company did not enter into any capital lease agreements. During the six months ended January 31, 2016, there was a total of $1,141 in capital lease agreements.

Inventories

Inventories	6 Months Ended
	Jan. 31, 2017
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Note 4 - Inventories Inventories consist of the following: January 31, July 31, Raw materials $ 912 $ 951 Work in process 1,893 1,755 Finished products 4,310 4,265 $ 7,115 $ 6,971

Goodwill and intangible assets

Goodwill and intangible assets	6 Months Ended
	Jan. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	Note 5 – Goodwill and intangible assets At January 31, 2017 and July 31, 2016, the Company’s net carrying amount of goodwill, related to the Clinical Labs segment, is $7,452. The Company’s change in the net carrying amount of intangible assets, all in the Life Sciences segment is as follows: Gross Accumulated Amortization Net July 31, 2016 $ 27,650 $ (23,228 ) $ 4,422 Amortization expense — (819 ) (819 ) Foreign currency translation (203 ) 160 (43 ) January 31, 2017 $ 27,447 $ (23,887 ) $ 3,560 Intangible assets, all finite lived, consist of the following: January 31, 2017 July 31, 2016 Gross Accumulated Net Gross Accumulated Net Patents $ 11,026 $ (10,922 ) $ 104 $ 11,027 $ (10,905 ) $ 122 Customer relationships 12,007 (8,739 ) 3,268 12,122 (8,331 ) 3,791 Website and acquired content 1,005 (1,005 ) — 1,011 (1,011 ) — Licensed technology and other 475 (440 ) 35 485 (437 ) 48 Trademarks 2,934 (2,781 ) 153 3,005 (2,544 ) 461 Total $ 27,447 $ (23,887 ) $ 3,560 $ 27,650 $ (23,228 ) $ 4,422 At January 31, 2017, information with respect to intangibles assets acquired is as follows: Useful life assigned Weighted average Customer relationships 8-15 years 3.5 years Trademarks 5 years 0.5 year Other intangibles 10 years 2.5 years At January 31, 2017, the weighted average useful life of intangible assets is approximately three years.

Loan Payable

Loan Payable	6 Months Ended
	Jan. 31, 2017
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 6 - Loan Payable On June 7, 2013, the Company entered into a secured Revolving Loan and Security Agreement (the “Credit Agreement”) among the Company and certain of its subsidiaries, with Enzo Therapeutics as a guarantor, and MidCap Financial LLC. (formerly Healthcare Finance Group, LLC). The nominal interest rate for the six months ended January 31, 2017 and year ended July 31, 2016 was 5.25%. The effective interest rate for the credit agreement was 14.3% for the six months ended January 31, 2017 and 11.4% for the fiscal year ended July 31, 2016. The Credit Agreement expired and was repaid in full on December 7, 2016.

Accrued Liabilities and Other C

Accrued Liabilities and Other Current Liabilities	6 Months Ended
	Jan. 31, 2017
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 7 – Accrued Liabilities and Other Current Liabilities Accrued liabilities consist of the following: January 31, July 31, Payroll, benefits, and commissions $ 3,737 $ 3,956 Legal fee expense 308 954 Professional fees 531 503 Research and development 72 300 Other 1,773 2,498 $ 6,421 $ 8,211

Other Liabilities

Other Liabilities	6 Months Ended
	Jan. 31, 2017
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Other Liabilities Disclosure [Text Block]	Note 8 – Other Liabilities Other liabilities consist of the following: January 31, July 31, Capital lease obligations, net of short term $ 635 $ 794 Accrued legal settlement 400 800 Installment loans, net of short term 63 105 $ 1,098 $ 1,699 As of January 31, 2017, future minimum payments under the capital leases, net of interest of $252 aggregates $771 including a short term debt portion of $136 included in other current liabilities. Future minimum payments under the installment loans aggregate $382, including a short term portion of $319 included in other current liabilities. A total of $0.4 million is included in other current liabilities and $0.4 million in other liabilities as accrued legal settlement which is further discussed in Note 12 - Contingencies.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jan. 31, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 9 – Stockholders’ Equity Controlled Equity Offering On March 28, 2013, the Company entered into a Controlled Equity Offering SM On December 31, 2014, the Sales Agreement was amended in order for the Company to offer and sell, through Cantor, acting as agent, additional shares of Common Stock having an aggregate offering price of $20.0 million. In connection with the amendment to the Sales Agreement, the Company also filed with the Security and Exchange Commission (“SEC”) a prospectus supplement dated December 31, 2014. Most recently with respect to the Sales Agreement, the Company filed a “shelf” registration and prospectus supplement dated September 1, 2016 which was declared effective by the SEC on November 3, 2016. During the six months ended January 31, 2017 and 2016, the Company did not sell any shares of Common Stock under the Sales Agreement. Share-based compensation The Company has an incentive stock option and restricted stock award plan (the “2005 Plan”), and a long term incentive share award plan, (the “2011 Incentive Plan”), which are more fully described in Note 10 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2016. The 2011 Plan, which is the only plan from which awards may now be granted, provides for the award to eligible employees, officers, directors, consultants and other persons of stock options, stock appreciation rights (SARs), restricted stock, restricted stock units, performance awards, and other stock-based awards. The amounts of share-based compensation expense recognized in the periods presented are as follows: Three months ended Six months ended 2017 2016 2017 2016 Stock options $ 236 $ 104 $ 382 $ 208 Restricted stock 5 6 10 13 $ 241 $ 110 $ 392 $ 221 The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations: Three months ended Six months ended 2017 2016 2017 2016 Cost of clinical laboratory services $ 1 $ 2 $ 3 $ 3 Selling, general and administrative 240 108 389 218 $ 241 $ 110 $ 392 $ 221 No excess tax benefits were recognized during the six month periods ended January 31, 2017 and 2016. Stock Option Plans The following table summarizes stock option activity during the six month period ended January 31, 2017: Options Weighted Weighted Aggregate Outstanding at July 31, 2016 1,808,875 $ 3.43 Awarded 493,996 $ 7.07 Exercised (23,096 ) $ 2.89 $ 149 Cancelled or expired (5,000 ) $ 4.47 Outstanding at end of period 2,274,775 $ 4.23 1.4 years $ 5,797 Exercisable at end of period 1,379,555 $ 3.18 0.5 years $ 4,853 As of January 31, 2017, the total future compensation cost related to non-vested options, not yet recognized in the statements of operations, was $1.6 million and the weighted average period over which the remaining expense of these awards is expected to be recognized is twenty-three months. The intrinsic value of in the money stock option awards that are vested at the end of the period represents the Company’s closing stock price on the last trading day of the period in excess of the exercise price multiplied by the number of options that vested. Restricted Stock Awards A summary of the activity pursuant to the Company’s unvested restricted stock awards for the six months ended January 31, 2017 is as follows: Awards Weighted Outstanding at July 31, 2016 8,501 $ 4.13 Awarded — — Vested (1,501 ) $ (3.89 ) Forfeited — — Unvested at end of period 7,000 $ 2.30 The fair value of a restricted stock award is determined based on the closing stock price on the award date. As of January 31, 2017, there was approximately $0.1 million of unrecognized compensation cost related to unvested restricted stock-based compensation to be recognized over a weighted average remaining period of approximately ten months. The fair value of the awards that vested during the six months ended January 31, 2017 and 2016 was $8 and $21, respectively. The total number of shares available for grant as equity awards from the 2011 Incentive Plan is approximately 329,000 shares as of January 31, 2017.

Income taxes

Income taxes	6 Months Ended
	Jan. 31, 2017
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 10 - Income taxes At the end of each interim reporting period, the Company estimates its effective income tax rate expected to be applicable for the full year. This estimate is used to determine the income tax provision or benefit on a year-to-date basis and may change in subsequent interim periods. The Company’s effective tax rate provision for the three months ended January 31, 2017 was 5.3% compared to 2.9% for the three months ended January 31, 2016. The Company’s effective tax rate provision for the six months ended January 31, 2017 and 2016 was 3.0% and 2.5%, respectively. The tax provision for the periods was based on state, local and foreign taxes. The Company’s effective tax rate for both periods differed from the expected net operating loss carryforward benefit at the U.S. federal statutory rate of 34% primarily due to the inability to recognize such benefit. The carryforward benefit cannot be recognized because of uncertainties relating to future taxable income in terms of both its timing and its sufficiency, which would enable the Company to realize the federal carryforward benefit. The Company files a consolidated Federal income tax return. The Company files combined returns with Michigan and New York State and City for certain subsidiaries. Other subsidiaries file separate state and foreign tax returns.

Segment reporting

Segment reporting	6 Months Ended
	Jan. 31, 2017
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	Note 11 – Segment reporting The Company has three reportable segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides diagnostic services to the health care community. The Life Sciences segment develops, manufactures, and markets products to research and pharmaceutical customers. The Therapeutic segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative costs which are not allocable to the three reportable segments. Legal fee expense incurred to defend the Company’s intellectual property and other general corporate matters is considered a component of the Other segment. Legal fee expense specific to other segments’ activities has been allocated to those segments. Legal settlements, net represent activities for which royalties would have been received by the Company’s Life Sciences segment had the Company had agreements in place with plaintiffs for the patents or products covered by the settlements. Management of the Company assesses assets on a consolidated basis only and, therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies contained in the Company’s Annual Report on Form 10-K for the year ended July 31, 2016. The following financial information represents the operating results of the reportable segments of the Company: Three months ended January 31, 2017 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 18,837 — — — $ 18,837 Product revenues — $ 6,983 — — 6,983 Royalty and license fee income — 440 — — 440 18,837 7,423 — — 26,260 Operating costs, expenses and legal settlements, net: Cost of clinical laboratory services 11,052 — — — 11,052 Cost of product revenues — 3,520 — — 3,520 Research and development — 516 $ (33 ) — 483 Selling, general and administrative 5,897 2,905 — $ 2,363 11,165 Provision for uncollectible accounts receivable 594 85 — — 679 Legal fee expense 49 16 — 305 370 Total operating costs, expenses and legal settlements, net 17,592 7,042 (33 ) 2,668 27,269 Operating income (loss) 1,245 381 33 (2,668 ) (1,009 ) Other income (expense): Interest (28 ) 12 — 95 79 Other 17 — — 7 24 Foreign exchange loss — (94 ) — — (94 ) Income (loss) before income taxes $ 1,234 $ 299 $ 33 $ (2,566 ) $ (1,000 ) Depreciation and amortization included above $ 394 $ 501 $ — $ 20 $ 915 Share-based compensation included in above: Cost of clinical laboratory services $ 1 — — — $ 1 Selling, general and administrative 23 $ 15 — $ 202 240 Total $ 24 $ 15 $ — $ 202 $ 241 Capital expenditures $ 175 $ — $ — $ — $ 175 Three months ended January 31, 2016 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 17,523 — — — $ 17,523 Product revenues — $ 6,578 — — 6,578 Royalty and license fee income — 459 — — 459 17,523 7,037 — — 24,560 Operating costs, expenses and legal settlements, net: Cost of clinical laboratory services 10,535 — — — 10,535 Cost of product revenues — 3,206 — — 3,206 Research and development — 661 $ 200 — 861 Selling, general and administrative 5,649 2,773 — $ 2,858 11,280 Provision for uncollectible accounts receivable 467 (8 ) — — 459 Legal fee expense 57 5 — 2,349 2,411 Legal settlements, net 1,500 (13,150 ) — — (11,650 ) Total operating costs, expenses and legal settlements, net 18,208 (6,513 ) 200 5,207 17,102 Operating income (loss) (685 ) 13,550 (200 ) (5,207 ) 7,458 Other income (expense) Interest (23 ) 17 — (36 ) (42 ) Other (1 ) — — 12 11 Foreign exchange loss — (388 ) — — (388 ) Income (loss) before income taxes $ (709 ) $ 13,179 $ (200 ) $ (5,231 ) $ 7,039 Depreciation and amortization included above $ 411 $ 524 $ — $ 17 $ 952 Share-based compensation included in above: Cost of clinical laboratory services $ 2 — — — $ 2 Selling, general and administrative 9 $ 5 — $ 94 108 Total $ 11 $ 5 $ — $ 94 $ 110 Capital expenditures $ 354 $ 84 $ — $ — $ 438 Six months ended January 31, 2017 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 37,395 — — — $ 37,395 Product revenues — $ 14,409 — — 14,409 Royalty and license fee income — 740 — — 740 37,395 15,149 — — 52,544 Operating costs, expenses and legal settlements, net: Cost of clinical laboratory services 21,948 — — — 21,948 Cost of product revenues — 6,829 — — 6,829 Research and development — 1,143 $ 162 — 1,305 Selling, general and administrative 11,849 5,851 — $ 4,939 22,639 Provision for uncollectible accounts receivable 1,260 88 — — 1,348 Legal fee expense 101 28 — 613 742 Total operating costs, expenses and legal settlements, net 35,158 13,939 162 5,552 54,811 Operating income (loss) 2,237 1,210 (162 ) (5,552 ) (2,267 ) Other income (expense): Interest (57 ) 22 — 160 125 Other 119 — — 24 143 Foreign exchange loss — (455 ) — — (455 ) Income (loss) before income taxes $ 2,299 $ 777 $ (162 ) $ (5,368 ) $ (2,454 ) Depreciation and amortization included above $ 795 $ 1,009 $ — $ 38 $ 1,842 Share-based compensation included in above: Cost of clinical laboratory services $ 3 — — — $ 3 Selling, general and administrative 40 $ 26 — $ 323 389 Total $ 43 $ 26 $ — $ 323 $ 392 Capital expenditures $ 587 $ 102 $ — $ — $ 689 Six months ended January 31, 2016 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 34,613 — — — $ 34,613 Product revenues — $ 14,265 — — 14,265 Royalty and license fee income — 859 — — 859 34,613 15,124 — — 49,737 Operating costs, expenses and legal settlements, net: Cost of clinical laboratory services 20,867 — — — 20,867 Cost of product revenues — 6,817 — — 6,817 Research and development — 1,328 $ 400 — 1,728 Selling, general and administrative 10,935 5,832 — $ 4,738 21,505 Provision for uncollectible accounts receivable 1,175 (12 ) — — 1,163 Legal fee expense 66 (17 ) — 3,963 4,012 Legal settlements, net 1,500 (19,950 ) — — (18,450 ) Total operating costs, expenses and legal settlements, net 34,543 (6,002 ) 400 8,701 37,642 Operating income (loss) 70 21,126 (400 ) (8,701 ) 12,095 Other income (expense) Interest (42 ) 31 — (71 ) (82 ) Other 3 39 — 23 65 Foreign exchange loss — (518 ) — — (518 ) Income (loss) before income taxes $ 31 $ 20,678 $ (400 ) $ (8,749 ) $ 11,560 Depreciation and amortization included above $ 808 $ 1,054 $ — $ 40 $ 1,902 Share-based compensation included in above: Cost of clinical laboratory services $ 3 — — — $ 3 Selling, general and administrative 19 $ 10 — $ 189 218 Total $ 22 $ 10 $ — $ 189 $ 221 Capital expenditures $ 791 $ 152 $ — $ — $ 943

Contingencies

Contingencies	6 Months Ended
	Jan. 31, 2017
Loss Contingency [Abstract]
Contingencies Disclosure [Text Block]	Note 12 – Contingencies On June 7, 2004, the Company and Enzo Life Sciences, Inc., filed suit in the United States District Court for the District of Connecticut against Applera Corporation and its wholly-owned subsidiary Tropix, Inc., which became Life Technologies, Inc. and was acquired by Thermo Fisher Scientific, Inc. (NYSE:TMO) on February 3, 2014. The complaint alleged infringement of six patents relating to DNA sequencing systems, labeled nucleotide products, and other technology. Yale University is the owner of four of the patents and the Company is the exclusive licensee. These four patents are commonly referred to as the “Ward” patents. On November 12, 2012, a jury in New Haven found that one of these patents (United States Patent No. 5,449,667) was infringed and not proven invalid. The jury awarded $48.5 million for this infringement. On January 6, 2014, the judge awarded prejudgment interest of approximately $12.5 million and additional post-interest on the full amount was also be awarded starting November 7, 2012 until the total award is satisfied. The final award to the Company could have been reduced or subject to possible claims from third parties. On March 16, 2015, the Court of Appeals for the Federal Circuit vacated that judgment in a decision remanding the matter to the district court for further proceedings. On February 22, 2016, the Connecticut District Court granted Applera’s motion for summary judgment of non-infringement. The Company appealed that decision to the Court of Appeals in the Federal Circuit. There can be no assurance that the Company will be successful in this litigation. Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on the Company. As of August 1, 2014 the Company was engaged in litigation in the United States District Court for the Southern District of New York against Roche Diagnostic GmbH and its related company Roche Molecular Systems, Inc. (“Roche”), as declaratory judgment defendant. This case was commenced in May 2004. Roche seeks a declaratory judgment of non-breach of contract and patent invalidity against the Company. Roche has also asserted tort claims against the Company. The Company has asserted breach of contract and patent infringement causes of action against Roche. There has been extensive discovery in the case. In 2011, Roche moved for summary judgment of non-infringement regarding the Company’s patent claims. In 2012, the motion was granted in part and denied in part. In December 2012, Roche moved for summary judgment on the Company’s non-patent claims. Additional discovery was taken and the Company responded to the motions in May 2013. On December 6, 2013, the Court granted in part and denied in part Roche’s summary judgment motion. On October 22, 2014, the Court ordered that damages discovery concerning the Company’s remaining contract and patent claims and Roche’s claims should be completed by January 30, 2015, and expert discovery should be completed following the Court’s not-yet-issued claim construction ruling concerning the Company’s patent infringement claim against Roche. Roche dropped its tort claims during damages discovery. On April 28, 2015, the Court heard oral argument on claim construction issues. On May 8, 2015, Roche and the Company jointly moved the Court to extend the schedule for damages discovery until May 29, 2015, and the Court granted that motion. The parties are waiting for the Courts’ ruling on claim construction. The Company and Enzo Life Sciences intend to vigorously press their remaining claims and contest the claims against them. On September 22, 2014, the Company and the U.S. Department of Justice reached a settlement agreement to resolve an investigation focused primarily on an alleged failure to collect diagnosis codes from physicians who ordered tests through Enzo Clinical Labs. During fiscal year 2014, the Company recorded a charge of $2.0 million in the statement of operations under legal settlements, net within the Clinical Labs segment. The settlement amount is being paid with interest over a five-year period. During fiscal year 2016, the Company accrued an additional $1.5 million, due to the Company’s achievement of certain financial milestones. As of January 31, 2017, the total liability for this settlement is $0.8 million, of which $0.4 million is included in other current liabilities and $0.4 million included in other liabilities. On June 20, 2014, the Company, as plaintiff finalized and executed a settlement agreement with PerkinElmer, Inc., and PerkinElmer Health Sciences, Inc. (formerly known as PerkinElmer Life Sciences, Inc.) (together, “PerkinElmer”), with respect to an action between the Company and PerkinElmer before the U.S. District Court, Southern District of New York, Case No 03-CV-3817. PerkinElmer paid $7.0 million in escrow pursuant to the agreement because of a former attorney’s charging lien for fees allegedly owed for past services rendered to the Company. On December 3, 2015, the Company entered into a Settlement Agreement with the former attorney pursuant to which the Company and the former attorney resolved their respective claims against each other. During the three months ended January 31, 2016, the Company received a total of approximately $7.0 million from the escrow referred to above in accordance with the terms of the Settlement Agreement which was included in the statement of operations under Legal settlements, net within the Life Science segment in that period. On October 9, 2015, the Company reached and finalized a settlement with Affymetrix, Inc. in the amount of $6.8 million, net in a patent infringement action brought by the Company. On January 4, 2016, the Company reached and finalized a settlement agreement with Agilent Technologies, Inc. in the amount of $6.1 million, net in a patent infringement action brought by the Company. Both cases were originally brought by the Company in the United States District Court for the District of Delaware. The settlements were included in the statement of operations during the applicable fiscal period under Legal settlements, net within the Life Science segment. On May 16, 2016, the Company reached and finalized a settlement with Life Technologies Corporation in the amount of $24.3 million, net in an infringement action brought by the Company regarding its US Patents No. 6,992,180 and 7,064,197. On July 1, 2016, the Company reached and finalized a settlement with Illumina, Inc., in the amount of $14.5 million, net in an infringement action brought by the Company regarding US Patent No. 7,064,197. These cases were originally brought by the Company in the United States District Court for the District of Delaware. The settlements are included in the statement of operations under Legal settlements, net within the Life Science segment for the fiscal year ended July 31, 2016. As of January 31, 2017, there are seven pending cases originally brought by the Company in the United States District Court for the District of Delaware alleging patent infringements against various companies. The Company is party to other claims, legal actions, complaints, and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial position or results of operations.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jan. 31, 2017
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Effect of New Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers: Topic 606 In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02 – Leases (Topic 842) In March 2016, the FASB issued ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting,” In April 2015, the FASB issued ASU No. 2015-03 Interest – Imputation of Interest. In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory (Topic 330). In January 2017, the FASB issued ASU 2017-04 Intangibles – Goodwill and Other – Simplifying the Test for Goodwill Impairment. The ASU eliminates step two in the current two-step process so that any goodwill impairment is measured as the amount by which the reporting unit’s carrying amount exceeds its fair value. The ASU is effective for the Company in the first quarter of 2020 with early adoption permitted. The Company does not expect the adoption of this ASU to have a material impact on our consolidated financial statements.

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jan. 31, 2017
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventories consist of the following: January 31, July 31, Raw materials $ 912 $ 951 Work in process 1,893 1,755 Finished products 4,310 4,265 $ 7,115 $ 6,971

Goodwill and intangible assets

Goodwill and intangible assets (Tables)	6 Months Ended
	Jan. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Indefinite-Lived Intangible Assets [Table Text Block]	The Company’s change in the net carrying amount of intangible assets, all in the Life Sciences segment is as follows: Gross Accumulated Amortization Net July 31, 2016 $ 27,650 $ (23,228 ) $ 4,422 Amortization expense — (819 ) (819 ) Foreign currency translation (203 ) 160 (43 ) January 31, 2017 $ 27,447 $ (23,887 ) $ 3,560
Schedule of Intangible Assets [Table Text Block]	Intangible assets, all finite lived, consist of the following: January 31, 2017 July 31, 2016 Gross Accumulated Net Gross Accumulated Net Patents $ 11,026 $ (10,922 ) $ 104 $ 11,027 $ (10,905 ) $ 122 Customer relationships 12,007 (8,739 ) 3,268 12,122 (8,331 ) 3,791 Website and acquired content 1,005 (1,005 ) — 1,011 (1,011 ) — Licensed technology and other 475 (440 ) 35 485 (437 ) 48 Trademarks 2,934 (2,781 ) 153 3,005 (2,544 ) 461 Total $ 27,447 $ (23,887 ) $ 3,560 $ 27,650 $ (23,228 ) $ 4,422
Schedule of Useful Lives For Acquisitions [Table Text Block]	At January 31, 2017, information with respect to intangibles assets acquired is as follows: Useful life assigned Weighted average Customer relationships 8-15 years 3.5 years Trademarks 5 years 0.5 year Other intangibles 10 years 2.5 years

Accrued Liabilities and Other23

Accrued Liabilities and Other Current Liabilities (Tables)	6 Months Ended
	Jan. 31, 2017
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued liabilities consist of the following: January 31, July 31, Payroll, benefits, and commissions $ 3,737 $ 3,956 Legal fee expense 308 954 Professional fees 531 503 Research and development 72 300 Other 1,773 2,498 $ 6,421 $ 8,211

Other Liabilities (Tables)

Other Liabilities (Tables)	6 Months Ended
	Jan. 31, 2017
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Schedule of Other Liabilities [Table Text Block]	Other liabilities consist of the following: January 31, July 31, Capital lease obligations, net of short term $ 635 $ 794 Accrued legal settlement 400 800 Installment loans, net of short term 63 105 $ 1,098 $ 1,699

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jan. 31, 2017
Stockholders' Equity Note [Abstract]
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]	The amounts of share-based compensation expense recognized in the periods presented are as follows: Three months ended Six months ended 2017 2016 2017 2016 Stock options $ 236 $ 104 $ 382 $ 208 Restricted stock 5 6 10 13 $ 241 $ 110 $ 392 $ 221
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations: Three months ended Six months ended 2017 2016 2017 2016 Cost of clinical laboratory services $ 1 $ 2 $ 3 $ 3 Selling, general and administrative 240 108 389 218 $ 241 $ 110 $ 392 $ 221
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes stock option activity during the six month period ended January 31, 2017: Options Weighted Weighted Aggregate Outstanding at July 31, 2016 1,808,875 $ 3.43 Awarded 493,996 $ 7.07 Exercised (23,096 ) $ 2.89 $ 149 Cancelled or expired (5,000 ) $ 4.47 Outstanding at end of period 2,274,775 $ 4.23 1.4 years $ 5,797 Exercisable at end of period 1,379,555 $ 3.18 0.5 years $ 4,853
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	A summary of the activity pursuant to the Company’s unvested restricted stock awards for the six months ended January 31, 2017 is as follows: Awards Weighted Outstanding at July 31, 2016 8,501 $ 4.13 Awarded — — Vested (1,501 ) $ (3.89 ) Forfeited — — Unvested at end of period 7,000 $ 2.30

Segment reporting (Tables)

Segment reporting (Tables)	6 Months Ended
	Jan. 31, 2017
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	The following financial information represents the operating results of the reportable segments of the Company: Three months ended January 31, 2017 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 18,837 — — — $ 18,837 Product revenues — $ 6,983 — — 6,983 Royalty and license fee income — 440 — — 440 18,837 7,423 — — 26,260 Operating costs, expenses and legal settlements, net: Cost of clinical laboratory services 11,052 — — — 11,052 Cost of product revenues — 3,520 — — 3,520 Research and development — 516 $ (33 ) — 483 Selling, general and administrative 5,897 2,905 — $ 2,363 11,165 Provision for uncollectible accounts receivable 594 85 — — 679 Legal fee expense 49 16 — 305 370 Total operating costs, expenses and legal settlements, net 17,592 7,042 (33 ) 2,668 27,269 Operating income (loss) 1,245 381 33 (2,668 ) (1,009 ) Other income (expense): Interest (28 ) 12 — 95 79 Other 17 — — 7 24 Foreign exchange loss — (94 ) — — (94 ) Income (loss) before income taxes $ 1,234 $ 299 $ 33 $ (2,566 ) $ (1,000 ) Depreciation and amortization included above $ 394 $ 501 $ — $ 20 $ 915 Share-based compensation included in above: Cost of clinical laboratory services $ 1 — — — $ 1 Selling, general and administrative 23 $ 15 — $ 202 240 Total $ 24 $ 15 $ — $ 202 $ 241 Capital expenditures $ 175 $ — $ — $ — $ 175 Three months ended January 31, 2016 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 17,523 — — — $ 17,523 Product revenues — $ 6,578 — — 6,578 Royalty and license fee income — 459 — — 459 17,523 7,037 — — 24,560 Operating costs, expenses and legal settlements, net: Cost of clinical laboratory services 10,535 — — — 10,535 Cost of product revenues — 3,206 — — 3,206 Research and development — 661 $ 200 — 861 Selling, general and administrative 5,649 2,773 — $ 2,858 11,280 Provision for uncollectible accounts receivable 467 (8 ) — — 459 Legal fee expense 57 5 — 2,349 2,411 Legal settlements, net 1,500 (13,150 ) — — (11,650 ) Total operating costs, expenses and legal settlements, net 18,208 (6,513 ) 200 5,207 17,102 Operating income (loss) (685 ) 13,550 (200 ) (5,207 ) 7,458 Other income (expense) Interest (23 ) 17 — (36 ) (42 ) Other (1 ) — — 12 11 Foreign exchange loss — (388 ) — — (388 ) Income (loss) before income taxes $ (709 ) $ 13,179 $ (200 ) $ (5,231 ) $ 7,039 Depreciation and amortization included above $ 411 $ 524 $ — $ 17 $ 952 Share-based compensation included in above: Cost of clinical laboratory services $ 2 — — — $ 2 Selling, general and administrative 9 $ 5 — $ 94 108 Total $ 11 $ 5 $ — $ 94 $ 110 Capital expenditures $ 354 $ 84 $ — $ — $ 438 Six months ended January 31, 2017 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 37,395 — — — $ 37,395 Product revenues — $ 14,409 — — 14,409 Royalty and license fee income — 740 — — 740 37,395 15,149 — — 52,544 Operating costs, expenses and legal settlements, net: Cost of clinical laboratory services 21,948 — — — 21,948 Cost of product revenues — 6,829 — — 6,829 Research and development — 1,143 $ 162 — 1,305 Selling, general and administrative 11,849 5,851 — $ 4,939 22,639 Provision for uncollectible accounts receivable 1,260 88 — — 1,348 Legal fee expense 101 28 — 613 742 Total operating costs, expenses and legal settlements, net 35,158 13,939 162 5,552 54,811 Operating income (loss) 2,237 1,210 (162 ) (5,552 ) (2,267 ) Other income (expense): Interest (57 ) 22 — 160 125 Other 119 — — 24 143 Foreign exchange loss — (455 ) — — (455 ) Income (loss) before income taxes $ 2,299 $ 777 $ (162 ) $ (5,368 ) $ (2,454 ) Depreciation and amortization included above $ 795 $ 1,009 $ — $ 38 $ 1,842 Share-based compensation included in above: Cost of clinical laboratory services $ 3 — — — $ 3 Selling, general and administrative 40 $ 26 — $ 323 389 Total $ 43 $ 26 $ — $ 323 $ 392 Capital expenditures $ 587 $ 102 $ — $ — $ 689 Six months ended January 31, 2016 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 34,613 — — — $ 34,613 Product revenues — $ 14,265 — — 14,265 Royalty and license fee income — 859 — — 859 34,613 15,124 — — 49,737 Operating costs, expenses and legal settlements, net: Cost of clinical laboratory services 20,867 — — — 20,867 Cost of product revenues — 6,817 — — 6,817 Research and development — 1,328 $ 400 — 1,728 Selling, general and administrative 10,935 5,832 — $ 4,738 21,505 Provision for uncollectible accounts receivable 1,175 (12 ) — — 1,163 Legal fee expense 66 (17 ) — 3,963 4,012 Legal settlements, net 1,500 (19,950 ) — — (18,450 ) Total operating costs, expenses and legal settlements, net 34,543 (6,002 ) 400 8,701 37,642 Operating income (loss) 70 21,126 (400 ) (8,701 ) 12,095 Other income (expense) Interest (42 ) 31 — (71 ) (82 ) Other 3 39 — 23 65 Foreign exchange loss — (518 ) — — (518 ) Income (loss) before income taxes $ 31 $ 20,678 $ (400 ) $ (8,749 ) $ 11,560 Depreciation and amortization included above $ 808 $ 1,054 $ — $ 40 $ 1,902 Share-based compensation included in above: Cost of clinical laboratory services $ 3 — — — $ 3 Selling, general and administrative 19 $ 10 — $ 189 218 Total $ 22 $ 10 $ — $ 189 $ 221 Capital expenditures $ 791 $ 152 $ — $ — $ 943

Net income (loss) per share (De

Net income (loss) per share (Details) - shares	3 Months Ended		6 Months Ended
	Jan. 31, 2017	Jan. 31, 2016	Jan. 31, 2017	Jan. 31, 2016
In the Money Stock Options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	888,000		888,000
Unvested Restricted Stock [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	804,000		804,000
Weighted Average Stock Options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Included In Computation Of Earnings Per Share Amount	440,000		281,000
Outstanding Options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	494,000	235,000	247,000	305,000

Supplemental disclosure for s28

Supplemental disclosure for statement of cash flows (Details) - USD ($) $ in Thousands	6 Months Ended
	Jan. 31, 2017	Jan. 31, 2016
Supplemental Cash Flow Elements [Abstract]
Income Taxes Paid	$ 996	$ 53
Interest Paid	77	77
Installment Loans Financed Amount	$ 69	76
Capital Lease Obligation Cost Basis		$ 1,141

Inventories (Details) - Schedul

Inventories (Details) - Schedule of inventory, current - USD ($) $ in Thousands	Jan. 31, 2017	Jul. 31, 2016
Schedule of inventory, current [Abstract]
Raw materials	$ 912	$ 951
Work in process	1,893	1,755
Finished products	4,310	4,265
	$ 7,115	$ 6,971

Goodwill and intangible asset30

Goodwill and intangible assets (Details) - USD ($) $ in Thousands	6 Months Ended
	Jan. 31, 2017	Jul. 31, 2016
Goodwill and intangible assets (Details) [Line Items]
Goodwill	$ 7,452	$ 7,452
Clinical Labs [Member]
Goodwill and intangible assets (Details) [Line Items]
Goodwill	$ 7,452	$ 7,452
Intangible Assets, Amortization Period [Member]
Goodwill and intangible assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	3 years

Goodwill and intangible asset31

Goodwill and intangible assets (Details) - Schedule of indefinite-lived intangible assets - USD ($) $ in Thousands	6 Months Ended
	Jan. 31, 2017	Jan. 31, 2016
Indefinite-lived Intangible Assets [Line Items]
July 31, 2016	$ 27,650
July 31, 2016	(23,228)
July 31, 2016	4,422
Amortization expense	(819)	$ (843)
Amortization expense	(819)	$ (843)
January 31, 2017	27,447
January 31, 2017	(23,887)
January 31, 2017	3,560
Life Sciences [Member]
Indefinite-lived Intangible Assets [Line Items]
July 31, 2016	27,650
July 31, 2016	(23,228)
July 31, 2016	4,422
Amortization expense	(819)
Amortization expense	(819)
Foreign currency translation	(203)
Foreign currency translation	160
Foreign currency translation	(43)
January 31, 2017	27,447
January 31, 2017	(23,887)
January 31, 2017	$ 3,560

Goodwill and intangible asset32

Goodwill and intangible assets (Details) - Schedule of intangible assets - USD ($) $ in Thousands	Jan. 31, 2017	Jul. 31, 2016
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	$ 27,447	$ 27,650
Finite-lived intangible assets, Accumulated Amortization	(23,887)	(23,228)
Finite-lived intangible assets, Net	3,560	4,422
Patents [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	11,026	11,027
Finite-lived intangible assets, Accumulated Amortization	(10,922)	(10,905)
Finite-lived intangible assets, Net	104	122
Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	12,007	12,122
Finite-lived intangible assets, Accumulated Amortization	(8,739)	(8,331)
Finite-lived intangible assets, Net	3,268	3,791
Website And Acquired Content [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	1,005	1,011
Finite-lived intangible assets, Accumulated Amortization	(1,005)	(1,011)
Licensed Technology And Other [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	475	485
Finite-lived intangible assets, Accumulated Amortization	(440)	(437)
Finite-lived intangible assets, Net	35	48
Trademarks [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	2,934	3,005
Finite-lived intangible assets, Accumulated Amortization	(2,781)	(2,544)
Finite-lived intangible assets, Net	$ 153	$ 461

Goodwill and intangible asset33

Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions	6 Months Ended
	Jan. 31, 2017
Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Weighted average remaining useful life	3 years 6 months
Trademarks [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	5 years
Weighted average remaining useful life	6 months
Other Intangible Assets [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	10 years
Weighted average remaining useful life	2 years 6 months
Minimum [Member] | Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	8 years
Maximum [Member] | Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	15 years

Loan Payable (Details)

Loan Payable (Details)	6 Months Ended	12 Months Ended
	Jan. 31, 2017	Jul. 31, 2016
Debt Disclosure [Abstract]
Nominal Interest Rate	5.25%	5.25%
Debt Instrument, Interest Rate During Period	14.30%	11.40%
Line of Credit Facility Expiration Month and Year	December 7, 2016

Accrued Liabilities and Other35

Accrued Liabilities and Other Current Liabilities (Details) - Accrued liabilities - USD ($) $ in Thousands	Jan. 31, 2017	Jul. 31, 2016
Accrued liabilities [Abstract]
Payroll, benefits, and commissions	$ 3,737	$ 3,956
Legal fee expense	308	954
Professional fees	531	503
Research and development	72	300
Other	1,773	2,498
	$ 6,421	$ 8,211

Other Liabilities (Details)

Other Liabilities (Details) - USD ($) $ in Thousands	Jan. 31, 2017	Jul. 31, 2016
Other Liabilities (Details) [Line Items]
Other Liabilities, Current	$ 859	$ 943
Accrued Legal Settlement Current	400
Accrued Legal Settlement	400
Capital Lease Obligation [Member] | Clinical Labs [Member]
Other Liabilities (Details) [Line Items]
Capital Leases, Future Minimum Payments, Interest Included in Payments	252
Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments	771
Other Liabilities, Current	136
Installment Loans [Member] | Clinical Labs [Member]
Other Liabilities (Details) [Line Items]
Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments	382
Other Liabilities, Current	$ 319

Other Liabilities (Details) - S

Other Liabilities (Details) - Schedule of other liabilities - USD ($) $ in Thousands	Jan. 31, 2017	Jul. 31, 2016
Other Liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities	$ 1,098	$ 1,699
Capital Lease Obligations [Member]
Other Liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities	635	794
Accrued Legal Settlement [Member]
Other Liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities	400	800
Installment Loans [Member]
Other Liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities	$ 63	$ 105

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	6 Months Ended
	Jan. 31, 2017	Jan. 31, 2016	Jul. 31, 2016	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Common Stock, Par or Stated Value Per Share (in Dollars per share)	$ 0.01		$ 0.01
Maximum Offering Price Under Sales Agreement	$ 20,000,000			$ 20,000,000
Percentage of Commission Payable on Equity Offering	3.00%
Excess Tax Benefit from Share-based Compensation, Financing Activities	$ 0	$ 0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 1,600,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	23 months
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 100,000
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Outstanding Weighted Average Remaining Contractual Terms	10 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 8,000	$ 21,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)	329,000

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Schedule of share-based compensation expense - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2017	Jan. 31, 2016	Jan. 31, 2017	Jan. 31, 2016
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Stock Based Compensation Expense	$ 241	$ 110	$ 392	$ 221
Options [Member]
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Stock Based Compensation Expense	236	104	382	208
Restricted Stocks [Member]
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Stock Based Compensation Expense	$ 5	$ 6	$ 10	$ 13

Stockholders' Equity (Details40

Stockholders' Equity (Details) - Schedule of share-based compensation expense by line item - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2017	Jan. 31, 2016	Jan. 31, 2017	Jan. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement	$ 241	$ 110	$ 392	$ 221
Cost of Clinical Laboratory Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement	1	2	3	3
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement	$ 240	$ 108	$ 389	$ 218

Stockholders' Equity (Details41

Stockholders' Equity (Details) - Schedule of stock option plans $ / shares in Units, $ in Thousands	6 Months Ended
	Jan. 31, 2017USD ($)$ / sharesshares
Schedule of stock option plans [Abstract]
Outstanding at July 31, 2016 | shares	1,808,875
Outstanding at July 31, 2016 | $ / shares	$ 3.43
Awarded | shares	493,996
Awarded | $ / shares	$ 7.07
Exercised | shares	(23,096)
Exercised | $ / shares	$ 2.89
Exercised | $	$ 149
Cancelled or expired | shares	(5,000)
Cancelled or expired | $ / shares	$ 4.47
Outstanding at end of period | shares	2,274,775
Outstanding at end of period | $ / shares	$ 4.23
Outstanding at end of period	1 year 146 days
Outstanding at end of period | $	$ 5,797
Exercisable at end of period | shares	1,379,555
Exercisable at end of period | $ / shares	$ 3.18
Exercisable at end of period	6 months
Exercisable at end of period | $	$ 4,853

Stockholders' Equity (Details42

Stockholders' Equity (Details) - Schedule of restricted stock awards	6 Months Ended
	Jan. 31, 2017$ / sharesshares
Schedule of restricted stock awards [Abstract]
Outstanding at July 31, 2016 | shares	8,501
Outstanding at July 31, 2016 | $ / shares	$ 4.13
Vested | shares	(1,501)
Vested | $ / shares	$ (3.89)
Unvested at end of period | shares	7,000
Unvested at end of period | $ / shares	$ 2.30

Income taxes (Details)

Income taxes (Details)	3 Months Ended		6 Months Ended
	Jan. 31, 2017	Jan. 31, 2016	Jan. 31, 2017	Jan. 31, 2016
Income Tax Disclosure [Abstract]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	5.30%	2.90%	3.00%	2.50%
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent			34.00%

Segment reporting (Details)

Segment reporting (Details)	6 Months Ended
	Jan. 31, 2017
Segment Reporting [Abstract]
Number of Reportable Segments	3

Segment reporting (Details) - S

Segment reporting (Details) - Schedule of segment reporting information, by segment - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2017	Jan. 31, 2016	Jan. 31, 2017	Jan. 31, 2016
Segment Reporting Information [Line Items]
Clinical laboratory services	$ 18,837	$ 17,523	$ 37,395	$ 34,613
Product revenues	6,983	6,578	14,409	14,265
Royalty and license fee income	440	459	740	859
Total revenues	26,260	24,560	52,544	49,737
Cost of clinical laboratory services	11,052	10,535	21,948	20,867
Cost of product revenues	3,520	3,206	6,829	6,817
Research and development	483	861	1,305	1,728
Selling, general and administrative	11,165	11,280	22,639	21,505
Provision for uncollectible accounts receivable	679	459	1,348	1,163
Legal fee expense	370	2,411	742	4,012
Legal settlements, net		(11,650)		(18,450)
Operating income (loss)	(1,009)	7,458	(2,267)	12,095
Other	24	11	143	65
Foreign exchange gain (loss)	(94)	(388)	(455)	(518)
Share-based compensation	241	110	392	221
Clinical Labs [Member]
Segment Reporting Information [Line Items]
Clinical laboratory services	18,837	17,523	37,395	34,613
Total revenues	18,837	17,523	37,395	34,613
Cost of clinical laboratory services	11,052	10,535	21,948	20,867
Selling, general and administrative	5,897	5,649	11,849	10,935
Provision for uncollectible accounts receivable	594	467	1,260	1,175
Legal fee expense	49	57	101	66
Legal settlements, net		1,500		1,500
Total operating expenses	17,592	18,208	35,158	34,543
Operating income (loss)	1,245	(685)	2,237	70
Interest	(28)	(23)	(57)	(42)
Other	17	(1)	119	3
Income (loss) before income taxes	1,234	(709)	2,299	31
Depreciation and amortization included above	394	411	795	808
Capital expenditures	175	354	587	791
Life Sciences [Member]
Segment Reporting Information [Line Items]
Product revenues	6,983	6,578	14,409	14,265
Royalty and license fee income	440	459	740	859
Total revenues	7,423	7,037	15,149	15,124
Cost of product revenues	3,520	3,206	6,829	6,817
Research and development	516	661	1,143	1,328
Selling, general and administrative	2,905	2,773	5,851	5,832
Provision for uncollectible accounts receivable	85	(8)	88	(12)
Legal fee expense	16	5	28	(17)
Legal settlements, net		(13,150)		(19,950)
Total operating expenses	7,042	(6,513)	13,939	(6,002)
Operating income (loss)	381	13,550	1,210	21,126
Interest	12	17	22	31
Other				39
Foreign exchange gain (loss)	(94)	(388)	(455)	(518)
Income (loss) before income taxes	299	13,179	777	20,678
Depreciation and amortization included above	501	524	1,009	1,054
Capital expenditures		84	102	152
Therapeutics [Member]
Segment Reporting Information [Line Items]
Research and development	(33)	200	162	400
Total operating expenses	(33)	200	162	400
Operating income (loss)	33	(200)	(162)	(400)
Income (loss) before income taxes	33	(200)	(162)	(400)
Other Segments [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative	2,363	2,858	4,939	4,738
Legal fee expense	305	2,349	613	3,963
Total operating expenses	2,668	5,207	5,552	8,701
Operating income (loss)	(2,668)	(5,207)	(5,552)	(8,701)
Interest	95	(36)	160	(71)
Other	7	12	24	23
Income (loss) before income taxes	(2,566)	(5,231)	(5,368)	(8,749)
Depreciation and amortization included above	20	17	38	40
Consolidated [Member]
Segment Reporting Information [Line Items]
Clinical laboratory services	18,837	17,523	37,395	34,613
Product revenues	6,983	6,578	14,409	14,265
Royalty and license fee income	440	459	740	859
Total revenues	26,260	24,560	52,544	49,737
Cost of clinical laboratory services	11,052	10,535	21,948	20,867
Cost of product revenues	3,520	3,206	6,829	6,817
Research and development	483	861	1,305	1,728
Selling, general and administrative	11,165	11,280	22,639	21,505
Provision for uncollectible accounts receivable	679	459	1,348	1,163
Legal fee expense	370	2,411	742	4,012
Legal settlements, net		(11,650)		(18,450)
Total operating expenses	27,269	17,102	54,811	37,642
Operating income (loss)	(1,009)	7,458	(2,267)	12,095
Interest	79	(42)	125	(82)
Other	24	11	143	65
Foreign exchange gain (loss)	(94)	(388)	(455)	(518)
Income (loss) before income taxes	(1,000)	7,039	(2,454)	11,560
Depreciation and amortization included above	915	952	1,842	1,902
Capital expenditures	175	438	689	943
Cost of Clinical Laboratory Services [Member]
Segment Reporting Information [Line Items]
Share-based compensation	1	2	3	3
Cost of Clinical Laboratory Services [Member] | Clinical Labs [Member]
Segment Reporting Information [Line Items]
Share-based compensation	1	2	3	3
Cost of Clinical Laboratory Services [Member] | Consolidated [Member]
Segment Reporting Information [Line Items]
Share-based compensation	1	2	3	3
Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	240	108	389	218
Selling, General and Administrative Expenses [Member] | Clinical Labs [Member]
Segment Reporting Information [Line Items]
Share-based compensation	23	9	40	19
Selling, General and Administrative Expenses [Member] | Life Sciences [Member]
Segment Reporting Information [Line Items]
Share-based compensation	15	5	26	10
Selling, General and Administrative Expenses [Member] | Other Segments [Member]
Segment Reporting Information [Line Items]
Share-based compensation	202	94	323	189
Selling, General and Administrative Expenses [Member] | Consolidated [Member]
Segment Reporting Information [Line Items]
Share-based compensation	240	108	389	218
Total [Member] | Clinical Labs [Member]
Segment Reporting Information [Line Items]
Share-based compensation	24	11	43	22
Total [Member] | Life Sciences [Member]
Segment Reporting Information [Line Items]
Share-based compensation	15	5	26	10
Total [Member] | Other Segments [Member]
Segment Reporting Information [Line Items]
Share-based compensation	202	94	323	189
Total [Member] | Consolidated [Member]
Segment Reporting Information [Line Items]
Share-based compensation	$ 241	$ 110	$ 392	$ 221

Contingencies (Details)

Contingencies (Details) $ in Millions	1 Months Ended							6 Months Ended	12 Months Ended
	Jul. 31, 2016USD ($)	May 31, 2016USD ($)	Jan. 31, 2016USD ($)	Oct. 31, 2015USD ($)	Jan. 31, 2014USD ($)	Nov. 30, 2012	Jun. 30, 2004	Jan. 31, 2017USD ($)	Jul. 31, 2016USD ($)	Jul. 31, 2014USD ($)	Jun. 20, 2014USD ($)
Contingencies (Details) [Line Items]
Gain Contingency, Patents Allegedly Infringed upon, Number							6
Number of Licensee Patents								4
Gain Contingency, Patents Found Not Infringed upon, Number						1
Gain Contingencies Prejudgement Interest					$ 12.5
Period Over Which Settlement Amount Has to Be Paid										5 years
Number Of Pending Cases								7
Perkin Elmer [Member]
Contingencies (Details) [Line Items]
Escrow Deposit											$ 7
Affymetrix Inc [Member]
Contingencies (Details) [Line Items]
Payments for Legal Settlements				$ 6.8
Agilent Technologies, Inc [Member]
Contingencies (Details) [Line Items]
Payments for Legal Settlements			$ 6.1
Life Technologies Corporation [Member]
Contingencies (Details) [Line Items]
Payments for Legal Settlements		$ 24.3
Illumina Inc [Member]
Contingencies (Details) [Line Items]
Payments for Legal Settlements	$ 14.5
Subpoena [Member]
Contingencies (Details) [Line Items]
Estimated Litigation Settlement Amount										$ 2
Additional Payment of Litigation Settlement Amount									$ 1.5
Total liability for settlement agreement								$ 0.8
Current liability for settlement agreement								0.4
Other liability for settlement agreement								0.4
Indemnification Agreement [Member]
Contingencies (Details) [Line Items]
Gain Contingency, Unrecorded Amount								$ 48.5